M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 42 of 54

COMPLETED

Asian Youth and Tobacco Control Survey

NCT00642317
COMPLETED NA

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755
COMPLETED Phase 2

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
COMPLETED Phase 3

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
COMPLETED Phase 1

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

NCT00645541
COMPLETED NA

Efficacy of the Third Eye Retroscope Auxiliary Imaging System

NCT00657371
COMPLETED NA

Patient and Family Decision Making in the Palliative Care Setting

NCT00682994
TERMINATED Phase 2

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

NCT00656916
TERMINATED Phase 2

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

NCT00640978
COMPLETED

Spirituality/Religiosity in Patients and Caregivers

NCT00634257
COMPLETED

Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program

NCT02747862
COMPLETED Phase 2

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

NCT00968071
COMPLETED Phase 1

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

NCT00631527
COMPLETED Phase 2

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

NCT00632359
COMPLETED NA

Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer

NCT00631241
TERMINATED Phase 2

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT01222195
TERMINATED Phase 2

Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

NCT00626561
TERMINATED NA

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742
TERMINATED Phase 3

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

NCT00634010
COMPLETED

Screening for Familial Colorectal Cancer (CRC) Patients

NCT00632515
COMPLETED NA

Interactive Voice Response System in Advanced Cancer Patients

NCT00625638
COMPLETED Phase 1

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

NCT00610493
TERMINATED Phase 1

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

NCT00543335
COMPLETED

Magnetic Resonance Imaging in Patients With Breast Cancer

NCT00610181
COMPLETED Phase 2

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

NCT00607113
COMPLETED

Social-Psychological Aspects of Orbital Exenteration

NCT00601744
COMPLETED Phase 2

Photopheresis for the Treatment of Acute Graft Versus Host Disease

NCT00609609
COMPLETED Phase 2

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628
COMPLETED Phase 1

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

NCT00614653
COMPLETED

Function and Balance for Inpatient Rehabilitation

NCT00601133
COMPLETED Phase 1

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

NCT00543842
COMPLETED

Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

NCT00592462
COMPLETED NA

Combined Treatment for Tobacco and Alcohol Use in Puerto Rico

NCT00570804
TERMINATED Phase 2

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

NCT00583622
TERMINATED

Retrospective Study of the Biomechanical Properties of Large Allografts

NCT00632294
TERMINATED

Carotid Artery Disease in Childhood Cancer Survivors

NCT00591539
TERMINATED Phase 1

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

NCT00555399
COMPLETED Phase 2

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

NCT00591630
COMPLETED Phase 1

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618
COMPLETED Phase 2

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
TERMINATED Phase 2

Role of Methadone As Co-Opioid Analgesic

NCT00558870
COMPLETED NA

Meditation and Cognitive Function in Women With Breast Cancer

NCT00556218
COMPLETED NA

Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00559611
COMPLETED Phase 1

Bevacizumab in Multiple Phase I Combinations

NCT00543504
COMPLETED

Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients

NCT01031602
COMPLETED Phase 1

Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)

NCT00538720
COMPLETED Phase 2

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

NCT00535873
COMPLETED

Female Sexual Dysfunction Intervention

NCT00614276
COMPLETED Phase 2

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder

NCT00963859
COMPLETED Phase 1

Trial of PBI-05204 in Advanced Cancer Patients

NCT00554268
← Previous Page 42 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.